摘要
目的:观察替罗非班对老年急性冠脉综合征(ACS)患者血清可溶性CD40配体(sCD40L)水平的影响。方法:将120例老年ACS患者,按照临床治疗方法分为非介入组(60例)和介入组(60例)。每组患者再随机分为两个亚组:对照组和替罗非班组。非介入组中的对照组应用阿司匹林、氯吡格雷、低分子肝素等常规药物治疗;替罗非班组则在对照组常规治疗的基础上加用盐酸替罗非班持续治疗72 h。介入组应用PCI,其中对照组在PCI术前嚼服阿司匹林和氯吡格雷,低分子肝素皮下注射,术中鞘内注射肝素;替罗非班组在常规治疗的同时,于PCI术前10 min开始以10μg/kg的替罗非班冠状动脉内注射。各组患者均在治疗前及治疗后48 h采用酶联免疫吸附测定(ELISA)法测定血清sCD40L水平。结果:介入组和非介入组的替罗非班组患者治疗后48 h的血清sCD40L浓度较治疗前明显降低,差异有统计学意义(P<0.05)。结论:替罗非班可以降低ACS患者的血清sCD40L水平,从而发挥除抗栓以外的抗炎作用。
Objective： To observe the effects that tirofiban had on serum sCD40L in acute coronary syndrome （ACS） patients. Methods： 120 ACS patients were divided into 2 groups according to different treatment methods： intervention group （60 cases） and nonintervention group （60 cases）. Then each group was divided into 2 subgroups randomly ： control group and tirofiban hydrochloride group. For the control group of the nonintervention one we used aspirin, clopidogrel, low molecular heparin and other treatments; for the tirofiban hydrochloride group we add tirofiban on the basis of routine treatments. Patients in the control group of the intervention one chewed aspirin, clopidogrel and low molecular heparin before the PCI operation, and took heparin intrathecal injection during the operation. For the tirofiban hydrochloride group, we used tirofiban intracoronary injection with the dosage of 101~g/kg since 10 minutes before the PCI operation. Then observe the 2 groups respectively on the changes of the concentration of serum sCD40L before the treatments and 48 hours after that. Results： The concentration of serum sCD40L of the tirofiban group in both the intervention and nonintervention group had reduced evidently 48 hours after the treatments. The difference was statistically significant （P 〈0.05）. Conclusion： Tirofiban can reduce the concentration of serum sCD40L in ACS patients, and produce an anti-inflammatory effect besides the antithrombotic one.
出处
《现代生物医学进展》
CAS
2014年第3期497-499,510,共4页
Progress in Modern Biomedicine
基金
黑龙江省卫生厅科研课题(2009-175)
